Glenmark Pharmaceuticals · NSE: GLENMARK · BSE: 532296
Q3 FY19 results · Oct–Dec 2018
Glenmark Pharmaceuticals reported revenue from operations of ₹2,555.05 crore and net profit of ₹116.34 crore for Q3 FY19 (Oct–Dec 2018), on a consolidated basis.
| Item | Q3 FY19 | Q3 FY18 | YoY | Q2 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,555.05 | — | — | 2,581.33 | −1.0% |
| Other income | (109.02) | — | — | 139.88 | Turned loss |
| Total income | 2,446.03 | — | — | 2,721.21 | −10.1% |
| Profit before tax | 154.03 | — | — | 579.59 | −73.4% |
| Net profit for the period | 116.34 | — | — | 414.00 | −71.9% |
| Attributable to shareholders of the company | 166.18 | — | — | 368.14 | −54.9% |
| EPS, basic (₹) | 4.12 | — | — | 14.67 | −71.9% |
| Net margin (%) | 4.6 | — | 16.0 |
| Item | Q3 FY19 | Q3 FY18 | YoY | Q2 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,632.04 | — | — | 1,679.71 | −2.8% |
| Other income | (84.64) | — | — | 226.30 | Turned loss |
| Total income | 1,547.39 | — | — | 1,906.02 | −18.8% |
| Profit before tax | 183.83 | — | — | 875.52 | −79.0% |
| Net profit for the period | 195.87 | — | — | 747.56 | −73.8% |
| EPS, basic (₹) | 6.94 | — | — | 26.49 | −73.8% |
| Net margin (%) | 12.0 | — | 44.5 |
Consolidated
- Filed with BSE
- 15 Feb 2019, 17:08 IST
- Board meeting
- 14 Feb 2019
- Period
- 01 Oct 2018 to 31 Dec 2018
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 15 Feb 2019, 17:08 IST
- Board meeting
- 14 Feb 2019
- Period
- 01 Oct 2018 to 31 Dec 2018
- Review status
- Unaudited
- Source
- XBRL filing on BSE